Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Poly [ADP-ribose] polymerase 12 (PARP12) is an interferon-stimulated, mono-ADP-ribosyltransferase enzyme, primarily located in the cytoplasm, notably at the Golgi apparatus, and can translocate to stress granules upon cellular stress. PARP12 plays key roles in antiviral defense by inhibiting viral mRNA translation, regulating inflammation via NF-κB signaling, and controlling intracellular trafficking. In cancer biology, PARP12 has been linked to chemoresistance, particularly in breast cancer, via regulation of the AKT survival pathway and protein translation. Its catalytic activity (mono-ADP-ribosylation) is crucial for many of these cellular effects. As a therapeutic target, it is less well characterized than PARP1/2 but has emerging roles in immunity and oncogenesis.
Mono-ADP-ribosylation of target proteins (e.g., AKT) to regulate their function; Inhibition of protein translation by associating with the translational machinery; Regulation of intracellular trafficking through stress-induced Golgi fragmentation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Poly [ADP-ribose] polymerase 12 (PARP12).